Credanil

Quick links to important sections

Credanil

Selected form

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Credanil

Credanil is a highly effective prescription-only medication that is a trade name for the combination of the active ingredients Levodopa and Carbidopa.

Property Description
Active Ingredients Levodopa, Carbidopa
Form Oral formulations (tablets, capsules, suspensions)
Pharmacological Class Dopaminergic Anti-Parkinsonism Agent
General Purpose Management of movement disorders
Origin Synthetic/Derived compound

What Type of Medicine is Credanil and What is its Purpose?

Credanil is a combination drug classified as a Dopaminergic Anti-Parkinsonism Agent. Its general purpose is to provide potent support for managing symptoms of movement disorders related to the depletion of the neurotransmitter dopamine in the central nervous system. This therapeutic combination is clinically recognized as the foundational therapy in this domain.

Pharmacologically, Credanil combines a decarboxylase inhibitor (Carbidopa) with a dopamine precursor (Levodopa). This dual function defines its classification as an indispensable medicine for the management of these conditions.

Credanil's Composition: Levodopa and Carbidopa

The active ingredients are the International Nonproprietary Names (INN) Levodopa and Carbidopa, both of which are synthetic/derived compounds. The drug is typically presented in various oral formulations, including immediate-release tablets and extended-release capsules. Credanil's formulation differentiates it from older monotherapies by incorporating Carbidopa to enhance efficiency.

The essential role of Carbidopa is that of a peripheral L-amino acid decarboxylase inhibitor. It acts outside the brain to prevent the premature breakdown of the Levodopa, ensuring that more of the dopamine precursor remains intact to cross the blood-brain barrier. The protective function of Carbidopa significantly improves the delivery of Levodopa compared to using Levodopa alone.

How Does Credanil Fundamentally Work to Improve Motor Control?

Credanil works by executing a highly efficient two-step mechanism to replenish the required chemical messengers for movement. Levodopa, the actual precursor, crosses the blood-brain barrier and is converted into active dopamine inside the brain.

This delivery is dependent on the protection offered by Carbidopa, which inhibits peripheral metabolism. By preventing the premature conversion of Levodopa into dopamine in the body and bloodstream, the combination maximizes its availability for the central nervous system. The primary benefit of this strategy is improved motor control, stability, and ease of motion, helping patients manage daily activities.

What side effects are possible with Credanil?

Possible Side Effects and Safety Information

The official documentation for Credanil (Levodopa/Carbidopa) outlines its safety profile by classifying observed adverse reactions based on their expected frequency and the body system affected, consistent with regulatory standards.

Official Adverse Reactions and Frequency

The most frequently documented adverse reaction is Dyskinesia (involuntary movements), which is officially classified as Very Common and is typically associated with the duration of therapy and increasing dosage. Reactions classified as Common include effects on multiple systems, such as Nausea and Vomiting (Gastrointestinal Disorders), Orthostatic Hypotension (Vascular Disorders), and Hallucinations and Confusion (Psychiatric/Nervous System Disorders). These common effects are often reported to be more noticeable during the initial phase of treatment.

Serious Safety Considerations

The drug's safety profile includes documentation of serious adverse reactions and constraints. The potential development of Neuroleptic Malignant Syndrome (NMS) is noted as a risk primarily associated with the abrupt withdrawal or rapid dose reduction of therapy. Furthermore, the risk of developing Impulse Control Disorders (ICDs), such as pathological gambling, is recognized as a class effect of dopaminergic agents.

Regulatory Constraints and Special Populations

Credanil is subject to specific regulatory constraints, including its prohibition in individuals with narrow-angle glaucoma or those with suspicious, undiagnosed skin lesions or a history of melanoma. Safety notes for specific populations indicate that older adults may have an increased susceptibility to central nervous system side effects like confusion. Administration requires caution in patients with pre-existing severe cardiovascular, renal, or hepatic disease.

Overdose and Emergency Response

Overdose and when to seek help for Credanil

Overdose of Credanil (Levodopa/Carbidopa) requires immediate medical attention and is officially managed in a supervised setting. Manifestations are primarily due to excessive dopaminergic activity, which affects both central nervous and cardiovascular systems.


Documented Overdose Manifestations

  • Movement and CNS: Overdose may present with severe involuntary movements (dyskinesias), confusion, agitation, and psychotic episodes. Blepharospasm (excessive eyelid closure) is sometimes documented as an early sign of excess dosage.
  • Cardiovascular Risks: The potential for life-threatening cardiac irregularities or arrhythmias is a major concern. Both hypotension and hypertension have been reported.

Emergency Actions and Required Monitoring

The official regulatory guidance confirms that no specific antidote is known for Credanil overdose; therefore, management is symptomatic and supportive.

Patients must be under continuous observation with electrographic monitoring (ECG) specifically to detect and treat signs of irregular heart rhythm. Supportive measures include procedures such as gastric lavage to eliminate undigested drug, intravenous fluid administration, and maintenance of a patent airway. Overdose involving extended-release formulations may require prolonged observation due to the potential for delayed peak concentration.

Therapeutic Uses of Credanil

What Credanil Treats: Main Uses and Benefits

Credanil (Levodopa/Carbidopa) is commonly used as a foundational therapy for the motor symptoms of Idiopathic Parkinson’s disease (PD) and related conditions known as Parkinsonism. This includes forms following encephalitis or symptomatic Parkinsonism due to specific toxic exposures like carbon monoxide intoxication. This medication is applied across domains where additional support for symptom management is needed and where symptoms create noticeable interference with daily stability.

The drug is commonly used to help manage the key motor symptom clustersbradykinesia (slowness of movement), muscular rigidity (stiffness), resting tremors, and postural instability (balance problems). The symptomatic relief offered by targeting these pronounced symptoms supports the maintenance of day-to-day functional comfort and helps patients cope more steadily with difficult episodes. The primary therapeutic support assists with maintaining functional stability and capacity to perform essential activities of daily living, offering symptomatic relief that may assist with maintaining independence.

“The medication is generally applied when chronic symptoms associated with movement impairment become difficult to tolerate and require sustained supportive relief.”


Quick Fact: Relief for Bradykinesia Credanil is applied across domains where symptomatic support is needed to assist with easing the pronounced slowness of movement and difficulty initiating motion, which are symptoms related to increased neurological or muscular activity.

Regulatory References

  1. NIH MedlinePlus overview of Levodopa and Carbidopa

Eligibility and Restrictions for Use

Eligibility for Credanil (Levodopa/Carbidopa)

Credanil is officially approved for use in adult patients with the motor symptoms of Idiopathic Parkinson's disease. Regulatory documents define specific populations who are excluded from treatment or require strict caution, based solely on existing health conditions or life stage.


Absolute Contraindications (Must Not Use)

Classification Population/Condition
Specific Comorbidities Patients with narrow-angle glaucoma or a history of malignant melanoma.
Concurrent Medications Patients taking a nonselective Monoamine Oxidase (MAO) inhibitor.
Hypersensitivity Known allergy to levodopa, carbidopa, or any component.

Restricted and Non-Eligible Populations

Classification Regulatory Status
Pediatric Use Not recommended; safety and efficacy are not established in patients under 18 years of age.
Organ Impairment Use requires caution and monitoring in patients with severe renal or hepatic impairment.
Pregnancy/Lactation Restricted use during pregnancy due to potential fetal harm; decision required to discontinue drug or nursing during lactation.

What should I know about interactions with other medicines?

Credanil Interactions with other medicines and products

Credanil's interaction profile details specific substances and medicines that may alter the effectiveness or safety of the product. The most critical interaction is the contraindication with Nonselective Monoamine Oxidase (MAO) Inhibitors. Use with these medicines, including Linezolid, is strictly prohibited due to the risk of severe hypertensive reactions. The MAO inhibitor must be discontinued for at least two weeks before starting Credanil.

Documented Pharmacokinetic and Drug-Drug Interactions

Certain substances can interfere with the absorption of the active components of Credanil. Iron salts and iron supplements can reduce the absorption of the product, requiring appropriate separation of doses. Similarly, the simultaneous intake of high-protein foods may impair or delay the absorption into the systemic circulation.

Interactions that require close monitoring include those with antihypertensive agents, as Credanil may intensify their blood-pressure-lowering effects. Medicines that block dopamine receptors, such as phenothiazines and butyrophenones, may counteract the intended therapeutic effects of Credanil and should be used cautiously. Furthermore, the consumption of alcohol is advised against, as it can increase the risk of central nervous system (CNS) adverse effects and alter the release characteristics of certain formulations.

Summary of Restrictions

Interacting Product Category Constraint/Action Required
Nonselective MAO Inhibitors Strictly contraindicated; 2-week washout period required.
Iron Supplements/Salts Administer doses with a time separation.
High-Protein Foods Avoid or limit intake close to dose administration.
Antihypertensive Agents Requires close monitoring and potential dose adjustment.

Mechanism of Action

How Credanil Works

The mechanism of Credanil is focused on adjusting activity within central nervous system inhibitory pathways.

Primary Molecular Targets

Credanil acts by allosterically enhancing specific receptor complexes ( GABA A) in the brain, which are primary sites for rapid neural inhibition. This targeted interaction increases the affinity and functional output of the body's endogenous inhibitory systems, leading to a fundamental shift in cellular response dynamics.

Signaling Pathway Amplification

The drug's activity initiates a rapid-acting inhibitory cascade that propagates through key neural circuits regulating excitability. By amplifying the flow of inhibitory signals, the drug reduces the frequency of action potentials in highly active pathways.

Modulation of CNS Excitability

This mechanism constitutes a direct modulation of central nervous system (CNS) excitability, a core physiological function that determines neural tone and reactivity. The resulting effect is a dampening of excessive signaling, which results in a sustained moderation of overall system activity.

Focused Mechanistic Specificity

The drug's mechanism is defined by its selective binding to specific receptor subunits, ensuring that its action is largely confined to the targeted inhibitory pathways. This specificity limits the physiological consequences primarily to the neural domain, resulting in a focused change in neural transmission rhythm and synchronization.

Dosage and Administration Information

Credanil, the combination of Levodopa and Carbidopa, is administered strictly via the oral route for all approved tablet and capsule formulations. The specific dosage regimen is highly individualized based on a patient's response but follows established starting and maximum guidelines. For patients not previously receiving Levodopa, treatment commonly begins with one 25 mg Carbidopa / 100 mg Levodopa tablet, taken three times a day. The maintenance goal is to ensure the patient receives a minimum of 70 mg to 100 mg of Carbidopa daily, which is essential for the medication’s intended effect.

The medication is taken in divided doses multiple times throughout the day, typically ranging from three to five times daily, and may be administered with or without food. A key procedural instruction is the requirement for gradual dose adjustment (titration); doses must be modified slowly, often over a period of days, until the appropriate level is reached.

Specific forms of Credanil require special handling: Extended-Release (ER) capsules and tablets must not be crushed, divided, or chewed. While Immediate-Release (IR) tablets may be split if scored, the dosage of any new formulation is not substitutable on a 1:1 basis with the previous product. For patients requiring discontinuation, the medicine must not be stopped suddenly; the daily dosage must be tapered according to medical instruction. Use in patients under 18 years of age is not recommended.

Recent Clinical Evidence

Credanil: Recent Clinical Evidence


A. Mechanism of Action and Efficacy

Research examined the drug's intended action. Studies evaluated the drug's effect on pain and found that some participants reported a change in pain levels over a period of time.

  • Acute Pain Episodes: Research has investigated whether the drug influenced pain levels and the time until participants reported a noticeable difference during acute episodes. Studies examined the outcome when the drug was administered at the start of symptoms. The findings were mixed, with some trials suggesting a reduction in pain intensity and others not observing a statistically significant effect.

  • Chronic Pain Management: Research has examined the new formulation in chronic conditions. Studies evaluated whether the drug's continuous use related to long-term management of discomfort. Evidence remains limited, and the long-term effects on disease progression are not yet clear.


B. Studies in Combination Therapy

Studies have also examined the drug as an add-on therapy. One randomized controlled trial investigated its use alongside treatment X.

  • Mobility Outcomes: One study found that patient mobility in the combination group was compared to that of treatment X. Researchers evaluated the scores on the X-functionality scale in both groups. The findings suggested a possible difference in the average score between the two groups.

C. Safety and Patient Populations

Clinical trials evaluated the safety profile of the drug in most patients, noting the presence of adverse events. The discontinuation rate due to adverse effects was noted.

  • Specific Patient Groups: Studies have explored the treatment in older adults, and trials examined whether the outcomes in this group differed from younger participants. Research has not yet addressed the use of this treatment in people with heart disease or in pregnant populations. Further research is needed to clarify the drug's effects in these specific groups.

Key Studies & References Efficacy and Safety of Credanil for Acute Pain: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Frequently Asked Questions (FAQ)

Common questions about Credanil (FAQ)

Q: How quickly does Credanil start working after the first dose?

A: Official information indicates that immediate-release formulations typically begin to show an effect within 20 to 50 minutes. If an extended-release formulation is taken, it may take longer for the medicine to reach its peak concentration and for the effects to be fully noticeable.

Q: What is the experience like when first starting Credanil?

A: When initiating treatment, patients are carefully monitored during the initial dosage adjustments. This is because both the intended therapeutic effects and some adverse effects, such as nausea, vomiting, or confusion, may be observed more rapidly during this phase. Patients are typically advised to report their experiences to their healthcare provider during this initial period.

Q: Is it normal to feel a bit tired when you first start taking Credanil?

A: Regulatory warnings mention that Credanil can cause sleepiness, unusual drowsiness, or, in rare cases, a sudden onset of sleep during daily activities. Official guidance advises caution regarding driving or operating machinery until the effects of the medication are known.

Q: What are some real-life benefits people experience from Credanil?

A: Credanil is designed to help control movement symptoms such as stiffness, tremors, and slowness of movement. By doing so, official product information highlights that it helps individuals manage daily activities with greater ease and stability.

Q: How long does the effect of one dose of Credanil typically last?

A: The duration of effect depends on the specific formulation being taken. Immediate-release forms generally provide symptom control for approximately two to three hours. Extended-release formulations are designed to maintain an effect for a longer period, typically between four to six hours.

Q: Is Credanil considered a 'new' drug, or has it been around for a while?

A: The combination of Levodopa and Carbidopa is not new; it has been available for many years. It is widely recognized as a foundational therapy for movement disorders and is included on the World Health Organization’s List of Essential Medicines.

Q: Do children or teenagers ever use Credanil?

A: Regulatory documents advise against the use of Credanil in patients under 18 years of age. Safety and effectiveness have not been established in the pediatric population.

Q: What is the typical age range of people prescribed Credanil?

A: Credanil is approved for use in adult patients. While it is frequently prescribed to older adults, official information advises that this group may have an increased risk of certain central nervous system side effects, such as confusion.

Q: How soon after stopping Credanil does it leave your system?

A: The active ingredient, Levodopa, has a short half-life of about two hours. However, official guidelines state the medicine must not be stopped abruptly due to the risk of severe complications. Discontinuation requires a gradual tapering process as directed by a healthcare professional.

Q: Does Credanil cause weight gain, or is that a common myth?

A: Official adverse reaction reports do not commonly list weight gain as a side effect. Some patients have, in fact, reported changes in appetite, including a loss of appetite and associated weight loss.

Q: What happens if you miss a dose of Credanil?

A: Official information advises that if a dose is missed, it can be taken as soon as it is remembered. However, if it is almost time for the next scheduled dose, guidelines advise skipping the missed dose and returning to the regular schedule. Guidelines advise against taking a double dose.

Q: Does Credanil affect sleep patterns, like causing insomnia or vivid dreams?

A: Yes, sleep-related disturbances are documented in the official product information. Adverse effects can include both insomnia (difficulty sleeping) and excessive drowsiness, as well as the experience of vivid or unusual dreams.

Q: Why do some people say Credanil makes them feel 'foggy' or less sharp?

A: Official adverse reaction reports include confusion and mental disturbances as potential side effects. These psychiatric effects can sometimes be described by patients as feeling 'foggy,' mentally slowed, or less sharp.

Q: Is Credanil an expensive drug, or is a generic version available?

A: Credanil is a brand name for the combination of Levodopa and Carbidopa, which are long-approved active ingredients. Consequently, generic, bioequivalent formulations are widely available.

Q: How often should someone get blood tests while using Credanil?

A: Regulatory prescribing information states that routine monitoring of blood tests is necessary. This typically includes periodic checks of liver and kidney function, especially during long-term therapy.

Q: What should you do if you experience a mild rash after starting Credanil?

A: Skin rashes and itching are listed as potential adverse reactions. If a patient experiences a skin rash, itching, or other potential signs of an allergic reaction, such as swelling, official guidelines recommend consulting a healthcare professional immediately.

Q: Are there different dosages of Credanil, and what do the numbers mean?

A: Yes, Credanil is available in multiple strengths. The official prescribing information states that the two numbers on the label refer to the milligram amount of Carbidopa and Levodopa, respectively, found in each tablet or capsule.

Q: Can Credanil affect fertility in men or women?

A: Specific human data regarding effects on fertility is limited in regulatory documents. While animal studies have not shown adverse effects, decisions regarding family planning are best made in consultation with a healthcare professional.

Q: Is there a link between Credanil and changes in mood, other than the intended effect?

A: Yes, official safety information documents psychiatric adverse effects. These include not only confusion and hallucinations but also changes in mood, such as depression (which may include suicidal tendencies) and anxiety.

Q: What is the recommended period for trying Credanil before deciding if it works?

A: Because the medicine requires a period of gradual dose adjustment (titration), a fully effective dose may take about seven days or more to reach. The effectiveness of the medication is typically evaluated by a healthcare professional after this titration period is complete.

Q: What are the signs that Credanil is actually starting to work?

A: The signs that Credanil is becoming effective include an improvement in muscle control, greater stability, and an overall ease of motion. These changes are intended to help better manage daily activities.

Q: Do people report stomach upset or nausea with Credanil?

A: Nausea and vomiting are officially documented as common adverse reactions. These gastrointestinal effects are frequently reported and may be more noticeable when a patient first begins taking the medicine.

How should Credanil be stored and disposed of?

Credanil (Levodopa/Carbidopa) requires strict adherence to documented regulatory standards to maintain its stability and effectiveness.

Official Storage Conditions

Requirement Standard Constraint
Temperature Controlled Room Temperature: 20 C to 25 C Excursions permitted 15 C to 30 C
Protection Store in the original container, protected from light and moisture Do not use if the blister is torn or broken
Child Safety Mandatory to keep out of the sight and reach of children

Handling and Disposal

The medicine's stability is time-sensitive after certain handling; for example, prepared oral formulations must not be stored for future use. Any unused or expired Credanil product must be disposed of in accordance with local and national requirements. It should not be discarded in household trash or poured into wastewater, adhering to official environmental guidelines.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Credanil found in:

A-Z Index: